SS&C Technologies (SSNC) Q2 2025 earnings review
Organic Growth Decelerates Despite Record Revenue; Intralinks Turns Negative
SS&C reported a solid quarter with record Adjusted Revenue of $1.54 billion (+5.9% YoY) and Adjusted EPS of $1.45 (+9.8%), beating expectations. However, the headline numbers mask a continued deceleration in organic growth, which slowed to 3.5% from 7.0% just two quarters ago. The slowdown was driven by a sharp reversal in the Intralinks segment (-4.5% organic growth) due to weak M&A markets. While the core GlobeOp fund administration business remains a key strength (+7.3%), growth is becoming more concentrated. The company raised its full-year guidance modestly, announced the strategic acquisition of Calastone, and continued its aggressive share repurchase program with $269 million in the quarter.
🐂 Bull Case
Adjusted EPS grew a strong 9.8% to $1.45, beating expectations. The company demonstrated excellent cost control, expanding its adjusted consolidated EBITDA margin by 50 basis points to a record 39.0%.
SS&C repurchased $269 million of stock in Q2 and has a new $1.5 billion authorization. This signals strong management confidence and provides a significant boost to EPS.
The GlobeOp fund administration business continues to be the primary growth engine, delivering robust 7.3% organic growth driven by strong demand in private markets and retail alternatives.
🐻 Bear Case
The core organic growth rate has declined for two consecutive quarters, from 7.0% in Q4 2024 to 3.5% in Q2 2025. This indicates a clear slowdown in underlying business momentum.
The Intralinks segment, a key contributor to growth in 2024, has reversed into negative territory with a -4.5% organic decline due to a weak M&A environment, creating a new headwind for the company.
Growth is becoming increasingly dependent on the GlobeOp segment as other large businesses like Wealth and Investment Technologies and GIDS have also seen their growth rates slow.
⚖️ Verdict: 🔴
Bearish. While margins are strong and buybacks support the stock, the clear trend of decelerating organic growth is a fundamental concern. The reversal in a key segment like Intralinks from a growth driver to a laggard cannot be overlooked. The raised guidance is modest and the Q3 outlook, while showing sequential improvement, is still well below prior peaks. The bearish case of slowing fundamentals is more compelling than the headline EPS beat.
Key Themes
Intralinks Reverses Sharply Amid M&A Slump
The most significant red flag this quarter was the performance of Intralinks, which reversed from 3.4% organic growth in Q1 to a -4.5% decline in Q2. Management directly attributed this to 'declines in global deal volume and active deal flow.' This shift turns a previous growth engine into a material headwind and highlights the company's exposure to the cyclical M&A market.
GlobeOp Remains the Growth Engine
The fund administration business, GlobeOp, continues to be the primary driver of performance with 7.3% organic growth. While this represents a deceleration from Q1's 10.3% rate, it is still very strong. Management cited continued momentum in complex areas like private markets (credit and hybrid funds) and retail alternatives, where the company's scale and technology are key differentiators.
Aggressive Share Repurchases Continue
Capital allocation remains heavily skewed towards shareholder returns. The company spent $269 million to buy back 3.4 million shares in Q2. Management's commitment was reinforced with a new $1.5 billion share repurchase authorization, signaling that returning capital is a top priority, especially as CEO Bill Stone noted M&A valuations are high.
Strategic M&A Returns with Calastone Acquisition
SS&C announced a definitive agreement to acquire Calastone, a global funds network, for approximately $1.03 billion. The deal expands SS&C's capabilities in ETFs, Digital Assets, and Money Market Products and provides access to new geographies. Management expects the acquisition to be accretive to revenue growth and EPS within 12 months, marking a return to strategic M&A.
Macroeconomic Headwinds are Broadening
Management attributed weakness in the Intralinks business to macroeconomic challenges impacting global deal volumes. While the company's diversification has historically provided resilience, the sharp reversal in this segment indicates that macro uncertainty is beginning to have a more tangible negative impact on specific business lines.
AI Strategy Shows First Commercial Success
The company's investment in AI is beginning to translate into revenue. Management highlighted the first sale of an 'AI agent' to an insurance conglomerate, which automates the processing of credit agreements. The agent is reported to reduce manual effort by up to 80% and improve accuracy. This represents an important proof point for monetizing the Blue Prism platform across SS&C's client base.
Healthcare Segment Remains Stagnant
The Healthcare segment reported 0.2% organic growth, effectively flat and continuing its trend of being a non-contributor to overall growth. Despite management's long-term optimism about its DomaniRx platform, the business has yet to show any meaningful traction.
Other KPIs
The company achieved a record quarterly EBITDA, growing 7.4% YoY. The corresponding margin expanded by 50 basis points to 39.0%, demonstrating strong cost control and operating leverage even as top-line growth decelerates.
Cash generation remains robust, with operating cash flow up 14.1% in the first half of 2025 compared to the prior year. This strong performance provides ample capacity for the company's aggressive share repurchase program and strategic acquisitions like Calastone.
The company's net leverage remains at a comfortable level, down from 2.94x in Q3 2024. This financial flexibility allows management to pursue its dual strategy of returning capital to shareholders while executing strategic acquisitions.
Guidance
Decelerating. The midpoint of $1,545M implies 5.3% YoY growth, a slowdown from Q2's 5.9% rate. However, the organic growth guidance of 4.5% implies a sequential acceleration from Q2's 3.5%, suggesting management expects the worst of the slowdown is over, though still well below the ~7% pace of late 2024.
Accelerating. The midpoint of $1.47 implies 14.0% YoY growth, an acceleration from Q2's 9.8% growth rate, likely driven by continued margin strength and the impact of share buybacks.
Stable. The full-year EPS guidance was raised by $0.10 at the midpoint to $5.94. This implies 9.8% growth over FY2024, a solid result but a deceleration from the 16.3% growth achieved in FY2024 (which was aided by a tax rate change).